Diabetes Dialogue: ADCES 2023 Recap
In this episode, which is the first of multiple special edition ADCES 2023 episodes, hosts hold an overarching discussion of the meeting itself and major themes from the ADCES's 50th anniversary celebration.
For the last 50 years, the Association of Diabetes Care and Education Specialists (ADCES) has stood alongside other leading organizations in the effort to improve and optimize management of diabetes.
Born in 1973 with the goal of creating an interprofessional membership organization dedicated to improving prediabetes, diabetes and cardiometabolic care, the organization has served a vital role within the field of diabetes management where, as a result of the constant evolution in understanding and management practices, the role of care and education specialists has gone from warranted to indispensable.
However, since a name change from the American Association of Diabetes Educators to the ADCES, the community has witnessed a proverbial explosion in the level of recognition and embrace for the role of diabetes care and education specialists as part of the diabetes care team. Nowhere is this continual evolving trend more evident than at the ADCES annual meeting.
The ADCES 2023 annual meeting was held in Houston, TX from August 4-7, 2023 and featured dozens of sessions highlighting a multitude of topics from presenters representing a variety of disciplines, including endocrinologists, pharmacists, advanced practice providers, dietitians, obesity specialists, and more. Active members and ardent supporters of the ADCES, Diana Isaacs, PharmD, and Natalie Bellini, DNP, hosts of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, have recorded multiple special edition episodes with an interest in highlighting the meeting, data presented, and to celebrate the meeting and the 50 year anniversary of the organization.
In the first of multiple ADCES 2023 recap episodes, Isaacs, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Bellini, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, break down a session Bellini led examining the embrace of time in range as a glucose metric, the role of diabetes care and education specialists in improving adoption of technology, bringing diabetes technology to primary care settings, and the fallacy of the rule of 15.
Relevant disclosures for Dr. Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Dr. Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.
